Helpline Tollfree +1.800.650.8239 info@clearsynth.com

OUR QUALITY: ISO 9001:2015 | ISO 14001:2015 | OHSAS 18001:2007 | ISO Guide 34:2009 | ISO/IEC 17025:2005

We speak your language 

N4-Benzoylcytosine

Intermediates
CAT No.
:
CS-O-11262

CAS No.

:

26661-13-2

Molecular Weight

:

215.21

Molecular Formula

:

C11H9N3O2

Purity

:

>98%

 


Useful information

"Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, or daclatasvir. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved. Safety during pregnancy is unclear; while, some of the medications used in combination may result in harm to the baby. It is taken by mouth.

Common side effects include feeling tired, headache, nausea, and trouble sleeping. Side effects are generally more common in interferon-containing regimens. Sofosbuvir may reactivate hepatitis B in those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat. Sofosbuvir is in the nucleotide analog family of medication and works by blocking the hepatitis C NS5B protein.

Sofosbuvir was discovered in 2007 and approved for medical use in the United States in 2013. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2016 a 12-week course of treatment costs about $84,000 in the United States, $53,000 in the United Kingdom, $45,000 in Canada, and $483 in India. Over 60,000 people were treated with sofosbuvir in its first 30 weeks being sold in the United States.",""



Product Application Notes

Intermediate of Sofosbuvir



References

Divya Rajagopal for the Economic Times. Sept 12, 2015;Tran TT (December 2012).



MSDS



Have any questions ?

We normally respond within 8 hours.

Subject :

  Stock Status

  Bulk Pricing

  Custom QTY Quote

  Request MSDS

  Request COA

  Other






Page info:

This page contains information about N4-Benzoylcytosine Cas # 26661-13-2 and its Intermediates.

N4-Benzoylcytosine N4-Benzoylcytosine Worldwide Suppliers of N4-Benzoylcytosine Intermediates Clearsynth 26661-13-2

Product rating: 9 N4-Benzoylcytosine based on 20 ratings

  1. Intermediates

  2. N4-Benzoylcytosine



Keywords

Keywords: Intermediates CS-O-11262 N4-Benzoylcytosine Sofosbuvir 26661-13-2 215.21 C11H9N3O2



Related result for 'N4-Benzoylcytosine'

- Sofosbuvir : API Standards

- Sofosbuvir : Stable Isotopes

- Sofosbuvir : Metabolites

- Sofosbuvir : Impurities

- Sofosbuvir : Intermediates



QUICK ENQUIRY

Specific product requirements



Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form :(






NORTH AMERICAN SALES AND R&D CENTRE

CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060

ASIA R&D CENTRE

CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
Hyderabad- 500076,
Telangana, India.
T : +91-40-27155481

ASIA OFFICE

CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
India
T : +91-22-45045945